Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Copanlisib in Combination With Rituximab and CHOP Chemotherapy in Patients With Previously Untreated DLBCL (COPA-R-CHOP)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04263584
Recruitment Status : Recruiting
First Posted : February 11, 2020
Last Update Posted : September 11, 2020
Sponsor:
Collaborator:
Bayer
Information provided by (Responsible Party):
University Hospital Muenster

Brief Summary:
This is a prospective, multicenter, non-randomized, open-label, phase II study to describe the efficacy of R-CHOP plus copanlisib including a safety run-in phase in order to detect early and common unexpected toxicities caused by the addition of copanlisib to the standard immuno-chemotherapy R-CHOP in patients with diffuse large B-cell lymphoma (DLBCL)

Condition or disease Intervention/treatment Phase
Diffuse Large B Cell Lymphoma Drug: Copanlisib Drug: R-CHOP Chemotherapy Phase 2

Detailed Description:
Patients diagnosed with DLBCL can be cured with a combined approach of CHOP chemotherapy and the anti-CD20 antibody rituximab in roughly 65% of cases. About one third of patients with DLBCL relapse or show primary progressive disease after modern first-line therapy. The outcome of these patients is poor in particular if first-line therapy contained rituximab. Novel therapeutic approaches are urgently warranted. Thus, it is the goal to further improve progression-free Survival (PFS) and overall Survival (OS) by combining R-CHOP with copanlisib. Copanlisib is a small molecule pan-class 1 PI3K inhibitor and approved by US FDA for the treatment of adult patients with relapsed follicular lymphoma who have received at least two prior systemic therapies.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 80 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Prospective Multicenter Phase 2 Study of Copanlisib in Combination With Rituximab and CHOP Chemotherapy (COPA-R-CHOP) in Patients With Previously Untreated Diffuse Large B-cell Lymphoma (DLBCL)
Actual Study Start Date : June 19, 2020
Estimated Primary Completion Date : June 2024
Estimated Study Completion Date : June 2024

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lymphoma
Drug Information available for: Copanlisib

Arm Intervention/treatment
Experimental: Copanlisib and R-CHOP chemotherapy
All patients will receive 6 cycles of R-CHOP immunochemotherapy every two weeks with the following doses per cycle: rituximab 375 mg/m², cyclophosphamide 750 mg/m², doxorubicin 50 mg/ m², vincristine 1.4 mg/m² (dose capped at 2 mg or 1 mg for individuals above 60 years of age), prednisolone 500 mg. In addition, copanlisib at a dose of 60 mg will be administered on days 1 and 8 of each 21-day cycle of R-CHOP in the first 6 patients. If dose limiting toxicity (DLT) occurs in no more than one out of these 6 patients during cycle 1, additional 6 patients at 60 mg will be enrolled and treated for at least 1 cycle before opening the phase II portion of the study. If a DLT is observed in 2 or more of the first 6 patients during cycle 1 the dose of copanlisib will be reduced to 45 mg on days 1 and 8 for the next 6 patients. The data of the safety run-in analysis (first 12 patients) will be presented to the Data Safety Monitoring Board and the recommended phase 2 dose will be determined.
Drug: Copanlisib
Copanlisib vials 60 mg

Drug: R-CHOP Chemotherapy
Immunochemotherapy




Primary Outcome Measures :
  1. 2-year progression-free survival [ Time Frame: From the day of inclusion into the study until event (disease progression, relapse, death due to any other cause) occurs, assessed up to 4 years. ]
    Length of time that a patient lives without disease progression or relapse.


Secondary Outcome Measures :
  1. Overall survival [ Time Frame: From the day of inclusion into the study to death due to any cause, assessed up to 4 years. ]
    The percentage of patients in this study who are still alive.

  2. Event-free survival [ Time Frame: From the day of inclusion into the study until event (disease progression, start of additional, unplanned anti-tumor therapy, relapse, death due to any other cause) occurs, assessed up to 4 years. ]
    Length of time that a patient remains free of certain events (disease progression, start of additional, unplanned antitumor therapy, relapse, death due to any other cause).

  3. Rate of complete remission [ Time Frame: From the day of inclusion into the study until date of complete remission, assessed up to 4 years. ]
    Rate of complete remission measured as number of complete remissions divided by the number of patients included.

  4. Rate of partial remission [ Time Frame: From the day of inclusion into the study until date of partial remission, assessed up to 4 years. ]
    Rate of partial remission measured as number of partial remissions divided by the number of patients included.

  5. Overall response rate [ Time Frame: From the day of inclusion into the study until date of complete or partial remission, assessed up to 4 years. ]
    Overall response rate measured as number of complete and partial remissions divided by the number of patients included.

  6. Progression rate [ Time Frame: From the day of inclusion into the study until date of progression during therapy or within 2 months after last treatment course. ]
    Progression rate measured as number of progressions divided by the number of patients included.

  7. Relapse rate [ Time Frame: From the day of inclusion into the study until date of relapse during therapy or within 2 months after last treatment course. ]
    Relapse rate measured as number of relapses divided by the number of patients included.

  8. Duration of response [ Time Frame: From documentation of tumor response to relapse, assessed up to 4 years. ]
    The time between the initial response to therapy and subsequent disease progression or relapse.

  9. Adverse events and serious adverse events [ Time Frame: The documentation of adverse events, including serious adverse events, starts with first study treatment after patient inclusion and ends 100 days after the last application of copanlisib or any component of R-CHOP ]
    Frequency of adverse events and serious adverse events

  10. Rate of treatment-related deaths [ Time Frame: From the start of therapy up to 2 months after the end of therapy. ]
    The number of deaths during therapy or up to 2 months after the end of therapy divided by the number of patients included.

  11. Therapy cycles (number) [ Time Frame: From the start of therapy (copanlisib and R-CHOP) until the end of therapy (last application of copanlisib or any component of R-CHOP), assessed up to 0.5 years. ]
    Number of therapy cycles

  12. Therapy cycles (duration) [ Time Frame: From the start of therapy (copanlisib and R-CHOP) until the end of therapy (last application of copanlisib or any component of R-CHOP), assessed up to 0.5 years. ]
    Duration of therapy cycles

  13. Used drugs [ Time Frame: From the start of therapy (copanlisib and R-CHOP) until the end of therapy (last application of copanlisib or any component of R-CHOP), assessed up to 0.5 years. ]
    Cumulative doses of R-CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone, rituximab) and copanlisib.

  14. Outcome according to lymphoma biology [ Time Frame: From the start of study until the end of study, assessed up to 4 years. ]
    Lymphoma tissue from all patients will be characterized.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Histologically confirmed

    1. DLBCL (NOS) or
    2. High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements or
    3. High-grade B-cell lymphoma (NOS)
    4. Follicular lymphoma Grade 3B (primary diagnosis without history of indolent lymphoma) with a diagnostic biopsy performed within 3 months before study entry and with material available for central review and complimentary scientific analyses
  2. 18-80 years of age
  3. International Prognostic Index (IPI) 2-5
  4. Eastern Cooperative Oncology Group Performance status (ECOG) 0-2
  5. Life expectancy of at least 3 months
  6. Women of childbearing potential and men must agree to use effective contraception when sexually active. This applies for the time period between signing of the informed consent form and 6 months after the last administration of study treatment. A woman is considered of childbearing potential, i.e. fertile, following menarche and until becoming post-menopausal unless permanently sterile. Permanent sterilization methods include but are not limited to hysterectomy, bilateral salpingectomy, and bilateral oophorectomy. A postmenopausal state is defined as no menses for continuous 12 months without an alternative medical cause. A high follicle stimulating hormone (FSH) level in the postmenopausal range may be used to confirm a post-menopausal state in women not using hormonal contraception or hormonal replacement therapy. The investigator or a designated associate is requested to advise the patient how to achieve highly effective birth control (failure rate of less than 1%), e.g. intrauterine device, intrauterine hormone-releasing system, bilateral tubal occlusion, vasectomized partner and sexual abstinence. The use of condoms by male patients is required unless the female partner is permanently sterile.

    Adequate baseline laboratory values collected no more than 7 days before starting study treatment:

  7. Total bilirubin ≤ 1.5 x ULN (< 3 x ULN for patients with Gilbert syndrome, patients with cholestasis due to compressive adenopathies of the hepatic hilum or documented liver involvement or with biliary obstruction due to lymphoma)
  8. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 x ULN (≤ 5 x ULN for patients with liver involvement by lymphoma)
  9. Lipase ≤ 1.5 x ULN
  10. Glomerular filtration rate (GFR) ≥ 40 mL/min/1.73 m2 according to the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula. If not on target, this evaluation may be repeated once after at least 24 hours either according to the CKD-EPI formula or by 24-hour sampling. If the later result is within acceptable range, it may be used to fulfill the inclusion criteria instead.
  11. INR and PTT ≤ 1.5 x ULN
  12. Platelet count ≥ 75,000 /mm3.
  13. Hemoglobin (Hb) ≥ 8 g/dL
  14. Absolute neutrophil count (ANC) ≥ 1,500/mm3
  15. Left ventricular ejection fraction ≥ 50%
  16. No prior lymphoma therapy
  17. Ability to understand and willingness to sign written informed consent. Signed informed consent must be obtained before any study specific procedure.

Exclusion Criteria:

Patients who meet any of the following criteria at the time of screening will be excluded.

  1. Previous assignment to treatment during this study. Patients permanently withdrawn from study participation will not be allowed to re-enter the study.
  2. Previous (within 28 days or less than 5 half-lives of the drug before start of study treatment) or concomitant participation in another clinical study with investigational medicinal product(s).
  3. Close affiliation with the investigational site; e.g. a close relative of the investigator, dependent persons (e.g. employee or student of the investigational site).

    Excluded medical conditions:

  4. Type I or II diabetes mellitus with HbA1c > 8.5% at screening or fasting plasma glucose > 160 mg/dL at screening
  5. History or concurrent condition of interstitial lung disease and/or severely impaired lung function (as judged by the investigator)
  6. Known lymphoma involvement of the central nervous system
  7. Human immunodeficiency virus (HIV) infection
  8. Hepatitis B (HBV) and C (HCV) infection. Patients with serologic markers of HBV immunization due to vaccination (HBsAg negative, Anti-HBc negative and Anti-HBs positive) will be eligible
  9. CMV-PCR positive at baseline
  10. Previous or concurrent history of malignancies within 5 years prior to study treatment except for curatively treated:

    1. Cervical carcinoma in situ
    2. Non-melanoma skin cancer
    3. Superficial bladder cancer (Ta [non-invasive tumor], Tis [carcinoma in situ] and T1 [tumor invades lamina propria])
    4. Localized prostate cancer
  11. Patients with evidence or history of bleeding diathesis. Any hemorrhage or bleeding event ≥ CTCAE Grade 3 within 4 weeks prior to the start of study medication
  12. Patients with seizure disorder requiring medication
  13. Proteinuria of ≥ CTCAE Grade 3 as assessed by a 24h protein quantification or estimated by urine protein: creatinine ratio > 3.5 on a random urine sample
  14. Concurrent diagnosis of pheochromocytoma
  15. Congestive heart failure > New York Heart Association (NYHA) class 2
  16. Unstable angina (angina symptoms at rest), new-onset angina (begun within the last 3 months)
  17. Myocardial infarction less than 6 months before start of test drug
  18. Arterial or venous thrombotic or embolic events such as cerebrovascular accident (including transient ischemic attacks), deep vein thrombosis or pulmonary embolism within 3 months before the start of study medication
  19. Non-healing wound, ulcer, or bone fracture
  20. Active, clinically serious infections > CTCAE Grade 2
  21. Uncontrolled hypertension (systolic blood pressure > 150 mmHg or diastolic pressure > 90 mmHg despite optimal medical management)
  22. Known history of drug induced liver injury, alcoholic liver disease, non-alcoholic steatohepatitis, primary biliary cirrhosis, on-going extra-hepatic obstruction caused by cholelithiasis, cirrhosis of the liver or portal hypertension
  23. Ongoing inflammatory bowel disease
  24. History of, or current autoimmune disease
  25. Prior treatment with PI3K inhibitors
  26. Any other co-existing medical or psychological condition that will preclude participation in the study or compromise ability to give informed consent
  27. Patient is pregnant (β-HCG positive) or breast-feeding
  28. Known hypersensitivity to copanlisib or to any of the excipients of rituximab, cyclophosphamide, doxorubicine, vincristine, and/or prednisone

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04263584


Contacts
Layout table for location contacts
Contact: Birte Friedrichs, MD +49 - (0)251 / 83 - 45375 copanlisib@ukmuenster.de

Locations
Layout table for location information
Germany
University Hospital Halle Recruiting
Halle (Saale), Germany, 06120
University Hospital Leipzig Recruiting
Leipzig, Germany, 04103
University Hospital Muenster Recruiting
Muenster, Germany, 48149
Hospital of the Ludwig-Maximilians-University (LMU) Munich Active, not recruiting
Munich, Germany, 81377
Hospital Stuttgart - Stuttgart Cancer Center Recruiting
Stuttgart, Germany, 70174
University Hospital Ulm Active, not recruiting
Ulm, Germany, 89081
Sponsors and Collaborators
University Hospital Muenster
Bayer
Investigators
Layout table for investigator information
Principal Investigator: Prof. Georg Lenz, MD University Hospital Muenster
Layout table for additonal information
Responsible Party: University Hospital Muenster
ClinicalTrials.gov Identifier: NCT04263584    
Other Study ID Numbers: UKM18-0021
First Posted: February 11, 2020    Key Record Dates
Last Update Posted: September 11, 2020
Last Verified: September 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by University Hospital Muenster:
Copanlisib
Additional relevant MeSH terms:
Layout table for MeSH terms
Lymphoma
Lymphoma, B-Cell
Lymphoma, Large B-Cell, Diffuse
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Lymphoma, Non-Hodgkin